CK2: A key player in cancer biology

Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been associated with increased cell growth and proliferation both in normal and cancer cells. The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer sinc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cellular and molecular life sciences : CMLS 2009-06, Vol.66, p.1858-1867
Hauptverfasser: Trembley, J. H., Wang, G., Unger, G., Slaton, J., Ahmed, K.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1867
container_issue
container_start_page 1858
container_title Cellular and molecular life sciences : CMLS
container_volume 66
creator Trembley, J. H.
Wang, G.
Unger, G.
Slaton, J.
Ahmed, K.
description Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been associated with increased cell growth and proliferation both in normal and cancer cells. The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer since deregulation of both cell proliferation and apoptosis are among the key features of cancer cell biology. Dysregulated CK2 may impact both of these processes in cancer cells. All cancers that have been examined show increased CK2 expression, which may also relate to prognosis. The extensive involvement of CK2 in cancer derives from its impact on diverse molecular pathways controlling cell proliferation and cell death. Downregulation of CK2 by various approaches results in induction of apoptosis in cultured cell and xenograft cancer models suggesting its potential as a therapeutic target.
doi_str_mv 10.1007/s00018-009-9154-y
format Article
fullrecord <record><control><sourceid>pubmedcentral</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4385580</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_4385580</sourcerecordid><originalsourceid>FETCH-LOGICAL-p210t-d4e555430b68b9cb68ecf3b4ec99154276cd3a4bbbf784bd7443eb3b524b55703</originalsourceid><addsrcrecordid>eNpVjk1LxDAYhIMo7of-AG8Fz9E3yZsm8SAsxY_FBS8K3kreNF2r3ba0q9B_b8W9eJl5YIZhGLsQcCUAzPUAAMJyAMed0MjHIzYXKIE7MOL4wKmVbzO2GIaPqaytTE_ZTDhljUY7Z5fZk7xJVslnHJOu9mPsk6pJgm_CRFS1dbsdz9hJ6eshnh98yV7v716yR755flhnqw3vpIA9LzBqrVEBpZZcmDSGUhHG4H7fSZOGQnkkotJYpMIgqkiKtETS2oBastu_3e6LdrEIsdn3vs67vtr5fsxbX-X_k6Z6z7ftd47Kam1B_QC-v002</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>CK2: A key player in cancer biology</title><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><creator>Trembley, J. H. ; Wang, G. ; Unger, G. ; Slaton, J. ; Ahmed, K.</creator><creatorcontrib>Trembley, J. H. ; Wang, G. ; Unger, G. ; Slaton, J. ; Ahmed, K.</creatorcontrib><description>Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been associated with increased cell growth and proliferation both in normal and cancer cells. The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer since deregulation of both cell proliferation and apoptosis are among the key features of cancer cell biology. Dysregulated CK2 may impact both of these processes in cancer cells. All cancers that have been examined show increased CK2 expression, which may also relate to prognosis. The extensive involvement of CK2 in cancer derives from its impact on diverse molecular pathways controlling cell proliferation and cell death. Downregulation of CK2 by various approaches results in induction of apoptosis in cultured cell and xenograft cancer models suggesting its potential as a therapeutic target.</description><identifier>ISSN: 1420-682X</identifier><identifier>EISSN: 1420-9071</identifier><identifier>DOI: 10.1007/s00018-009-9154-y</identifier><identifier>PMID: 19387548</identifier><language>eng</language><ispartof>Cellular and molecular life sciences : CMLS, 2009-06, Vol.66, p.1858-1867</ispartof><rights>Birkhäuser Verlag, Basel, 2009 2009</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385580/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4385580/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids></links><search><creatorcontrib>Trembley, J. H.</creatorcontrib><creatorcontrib>Wang, G.</creatorcontrib><creatorcontrib>Unger, G.</creatorcontrib><creatorcontrib>Slaton, J.</creatorcontrib><creatorcontrib>Ahmed, K.</creatorcontrib><title>CK2: A key player in cancer biology</title><title>Cellular and molecular life sciences : CMLS</title><description>Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been associated with increased cell growth and proliferation both in normal and cancer cells. The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer since deregulation of both cell proliferation and apoptosis are among the key features of cancer cell biology. Dysregulated CK2 may impact both of these processes in cancer cells. All cancers that have been examined show increased CK2 expression, which may also relate to prognosis. The extensive involvement of CK2 in cancer derives from its impact on diverse molecular pathways controlling cell proliferation and cell death. Downregulation of CK2 by various approaches results in induction of apoptosis in cultured cell and xenograft cancer models suggesting its potential as a therapeutic target.</description><issn>1420-682X</issn><issn>1420-9071</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><recordid>eNpVjk1LxDAYhIMo7of-AG8Fz9E3yZsm8SAsxY_FBS8K3kreNF2r3ba0q9B_b8W9eJl5YIZhGLsQcCUAzPUAAMJyAMed0MjHIzYXKIE7MOL4wKmVbzO2GIaPqaytTE_ZTDhljUY7Z5fZk7xJVslnHJOu9mPsk6pJgm_CRFS1dbsdz9hJ6eshnh98yV7v716yR755flhnqw3vpIA9LzBqrVEBpZZcmDSGUhHG4H7fSZOGQnkkotJYpMIgqkiKtETS2oBastu_3e6LdrEIsdn3vs67vtr5fsxbX-X_k6Z6z7ftd47Kam1B_QC-v002</recordid><startdate>20090601</startdate><enddate>20090601</enddate><creator>Trembley, J. H.</creator><creator>Wang, G.</creator><creator>Unger, G.</creator><creator>Slaton, J.</creator><creator>Ahmed, K.</creator><scope>5PM</scope></search><sort><creationdate>20090601</creationdate><title>CK2: A key player in cancer biology</title><author>Trembley, J. H. ; Wang, G. ; Unger, G. ; Slaton, J. ; Ahmed, K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p210t-d4e555430b68b9cb68ecf3b4ec99154276cd3a4bbbf784bd7443eb3b524b55703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Trembley, J. H.</creatorcontrib><creatorcontrib>Wang, G.</creatorcontrib><creatorcontrib>Unger, G.</creatorcontrib><creatorcontrib>Slaton, J.</creatorcontrib><creatorcontrib>Ahmed, K.</creatorcontrib><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cellular and molecular life sciences : CMLS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Trembley, J. H.</au><au>Wang, G.</au><au>Unger, G.</au><au>Slaton, J.</au><au>Ahmed, K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CK2: A key player in cancer biology</atitle><jtitle>Cellular and molecular life sciences : CMLS</jtitle><date>2009-06-01</date><risdate>2009</risdate><volume>66</volume><spage>1858</spage><epage>1867</epage><pages>1858-1867</pages><issn>1420-682X</issn><eissn>1420-9071</eissn><abstract>Elevated levels of protein kinase CK2 (formerly casein kinase 2 or II) have long been associated with increased cell growth and proliferation both in normal and cancer cells. The ability of CK2 to also act as a potent suppressor of apoptosis offers an important link to its involvement in cancer since deregulation of both cell proliferation and apoptosis are among the key features of cancer cell biology. Dysregulated CK2 may impact both of these processes in cancer cells. All cancers that have been examined show increased CK2 expression, which may also relate to prognosis. The extensive involvement of CK2 in cancer derives from its impact on diverse molecular pathways controlling cell proliferation and cell death. Downregulation of CK2 by various approaches results in induction of apoptosis in cultured cell and xenograft cancer models suggesting its potential as a therapeutic target.</abstract><pmid>19387548</pmid><doi>10.1007/s00018-009-9154-y</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1420-682X
ispartof Cellular and molecular life sciences : CMLS, 2009-06, Vol.66, p.1858-1867
issn 1420-682X
1420-9071
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4385580
source PubMed Central; SpringerLink Journals - AutoHoldings
title CK2: A key player in cancer biology
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T22%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CK2:%20A%20key%20player%20in%20cancer%20biology&rft.jtitle=Cellular%20and%20molecular%20life%20sciences%20:%20CMLS&rft.au=Trembley,%20J.%20H.&rft.date=2009-06-01&rft.volume=66&rft.spage=1858&rft.epage=1867&rft.pages=1858-1867&rft.issn=1420-682X&rft.eissn=1420-9071&rft_id=info:doi/10.1007/s00018-009-9154-y&rft_dat=%3Cpubmedcentral%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_4385580%3C/pubmedcentral%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/19387548&rfr_iscdi=true